Archive | Clinical Sites & Recruitment RSS feed for this section

Recent Findings in PPMI

by Krishna Knabe The Michael J. Fox Foundation A group of authors led by PPMI’s principal investigator, Dr. Kenneth Marek, published baseline data from the study in the Annals of Clinical and Translational Neurology. The paper includes detailed biomarker signatures on the initial volunteer groups, which include patients with Parkinson’s disease, healthy controls and those who […]

Continue reading...

PPMI Study Enters a New Phase

by Krishna Knabe The Michael J. Fox Foundation The Parkinson’s Progression Markers Initiative (PPMI) has reached an important milestone: the study completed enrollment. We have now met the ambitious goal we set back in 2010 of enrolling 1,400 participants, including 600 with rare genetic mutations. PPMI is The Michael J. Fox Foundation’s landmark observational clinical […]

Continue reading...

PPMI Study Update Call – 6/14/18

PPMI Study Update Call Cerebrospinal Fluid Analysis Thursday, June 14 12-1 pm Eastern Time Brit Mollenhauer, MD Attending Neurologist, Head of Clinical Research PPMI Steering Committee Member Paracelsus-Elena Klinik Doug Galasko, MD Professor of Neurology PPMI Steering Committee Member University of California San Diego   PPMI participants are encouraged to call in to the next […]

Continue reading...

Collaboration with Verily Aims to Deepen Parkinson’s Understanding through Digital Health Tools

Wearable sensors to monitor health-related measures like heart rate, glucose levels, or physical activity are helping people assess their own health and enabling research in treating and understanding chronic disease. The Michael J. Fox Foundation (MJFF) and Verily Life Sciences LLC, an Alphabet company, are collaborating to use wearable devices — in conjunction with clinic-based data and […]

Continue reading...

PPMI Study Update Call – 3/15/18

PPMI Study Update Call Thursday, March 15 12-1 pm Eastern Time Andrew Siderowf, MD, MSCE Professor of Neurology University of Pennsylvania Co-Principal Investigator of PPMI   PPMI participants are encouraged to call in to the next quarterly Study Update Call on Thursday, March 15, 2018 at 12 pm EST.  During this call, Dr. Andrew Siderowf, […]

Continue reading...

PPMI iPSC Lines — A Valuable Tool for Researchers

The Parkinson?s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]

Continue reading...

2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

Continue reading...

Reform Movement and The Michael J. Fox Foundation Team Up for Study Investigating Genetic Mutations Common in Jews

Religious Action Center of Reform Judaism Director Rabbi Jonah Pesner: ?This study provides an important opportunity to help potentially stamp out an insidious disease and reflects the Jewish imperative toward pikuach nefesh, the saving of a life.?

Continue reading...

Understanding the Genetic Widespread Recruitment Initiative

The Widespread Recruitment Initiative (WRI) is an internet-based recruitment tool that allows potential PPMI participants to be screened, consented and provided with LRRK2 testing without having to visit a PPMI site. Find out how the process works.

Continue reading...

PPMI Annual Meeting 2014 Summary

On May 6 and 7, PPMI held its 2014 Annual Investigators Meeting in New York, NY. Participants included site investigators and coordinators, study and sponsor staff, industry partners, and Steering Committee, Patient Advisory Committee, and study core members representing 15 countries and about 60 companies and organizations. View this year's presentations.

Continue reading...